EyeEm Mobile GmbH/iStock via Getty Images GSK ( NYSE: GSK ) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older. The British.
Back to Health Page
